Fennec Pharmaceuticals (RV41) Price & Analysis

0 Followers

RV41 Stock Chart & Stats

€10.60

-€0.45(-5.14%)

At close: Jul 29 4:00 PM EDT

€10.60

-€0.45(-5.14%)

Day’s Range― - ―

52-Week Range€4.74 - €11.10

Previous CloseN/A

Volume0.00

Average Volume (3M)1.00

Market Cap

€315.54M

Enterprise Value€350.37M

Total Cash (Recent Filing)€41.25M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.90

Next Earnings

Nov 05, 2026

EPS Estimate

0.08

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding35,067,158

10 Day Avg. Volume0

30 Day Avg. Volume1

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)6.28

Price to Sales (P/S)4.93

P/FCF Ratio-17.64

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€15.71

Price Target Upside48.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)0.27

Revenue Forecast (FY)€64.88M

Bulls Say, Bears Say

Bulls Say

Commercial GrowthRapid product-sales growth and a seventh consecutive quarter of expansion indicate increasing PEDMARK adoption. Record infusions, enrollments, active patients, and customers suggest that commercial momentum is broadening and could support stronger operating leverage over the next several quarters.

High Gross MarginThe exceptionally high gross margin indicates attractive economics for the commercialized product and leaves substantial revenue available to fund selling, medical, and corporate activities. As sales scale, these economics can provide meaningful leverage toward durable operating profitability.

Debt-Free Balance SheetZero debt and rebuilt positive equity materially reduce financing pressure and improve strategic flexibility. The stronger capital structure gives Fennec more capacity to support commercialization and absorb operating volatility without relying primarily on additional borrowing.

Bears Say

Negative Cash FlowFennec is not yet consistently self-funding despite improving losses and sales. Persistent negative and historically volatile cash generation can limit reinvestment flexibility, increase dependence on the existing cash position, and make execution more sensitive to changes in collections or spending.

Revenue ConcentrationHeavy reliance on three tumor types creates a concentrated revenue base rather than a broadly diversified commercial franchise. Changes in treatment patterns, adoption, or access within any major segment could therefore have an outsized effect on PEDMARK demand and future growth.

Rising Commercial CostsHigher marketing and commercial headcount spending is supporting expansion, but it also raises the level of revenue required to sustain profitability. If newly targeted prescribers and territories ramp more slowly than expected, operating leverage and cash generation could remain pressured.

Fennec Pharmaceuticals News

Fennec’s Pedmark Trial in Japan Shows Strong Hearing Protection Without Hurting Tumor Response

Fennec Pharmaceuticals ( ($FENC) ) just unveiled an announcement. Fennec Pharmaceuticals reported detailed results from the investigator-initiated Phase...

1M ago

FENC

Fennec presents results from STS-J01 clinical trial evaluating Pedmark

Fennec (FENC) announced the oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating...

1M ago

FENC

Analyst Reaffirms Buy on Fennec’s PEDMARK Momentum and Growth Catalysts, Maintains $16 12-Month Target

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Fennec Pharmaceuticals, with a price target of...

2M ago

FENC

Fennec Pharmaceuticals Earnings Call Highlights Strong Momentum

Fennec Pharmaceuticals (($FENC)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

FENC

Fennec price target raised to $16 from $13 at Wedbush

Wedbush raised the firm’s price target on Fennec (FENC) to $16 from $13 and keeps an Outperform rating...

2M ago

FENC

Fennec price target raised to $18 from $16 at B. Riley

B. Riley raised the firm’s price target on Fennec (FENC) to $18 from $16 and keeps a Buy...

2M ago

FENC

Fennec reports Q2 EPS 5c, consensus 2c

Reports Q2 revenue $17.87M, consensus $16.12M. “Our second quarter reflects another period of strong execution across the business,...

2M ago

FENC

FENC Upcoming Earnings Report: What to Expect?

Fennec Pharmaceuticals (FENC) is scheduled to report 2nd quarter earnings on 08/11/2026, before the market opens. Regarding Q2...

3M ago

FENC

Fennec Shareholders Approve Governance, Compensation and Equity Plans

Fennec Pharmaceuticals ( ($TSE:FRX) ) has issued an announcement. On June 10, 2026, Fennec Pharmaceuticals Inc. held its...

5M ago

FENC

Fennec Showcases New PEDMARK Data at ASCO 2026

An announcement from Fennec Pharmaceuticals ( ($TSE:FRX) ) is now available. On May 21, 2026, Fennec Pharmaceuticals announced...

5M ago

FENC

Fennec price target raised to $16 from $13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Fennec (FENC) to $16 from $13 and keeps a Buy...

5M ago

FENC

Fennec Pharmaceuticals Earnings Call Signals Robust Growth

Fennec Pharmaceuticals (($TSE:FRX)) has held its Q1 earnings call. Read on for the main highlights of the call....

5M ago

FENC

Fennec reports Q1 EPS 1c, consensus (2c)

Reports Q1 revenue $15.1M, consensus $13.84M. “We are encouraged by our continued quarter-over-quarter growth and strong start to...

5M ago

FENC

Fennec Showcases New PEDMARK Data at 2026 ASCO

Fennec Pharmaceuticals ( ($TSE:FRX) ) has shared an update. On April 21, 2026, Fennec Pharmaceuticals announced that four...

6M ago

FENC

RV41 FAQ

What was Fennec Pharmaceuticals’s price range in the past 12 months?

Fennec Pharmaceuticals lowest stock price was €4.74 and its highest was €11.10 in the past 12 months.

What is Fennec Pharmaceuticals’s market cap?

Fennec Pharmaceuticals’s market cap is €315.54M.

When is Fennec Pharmaceuticals’s upcoming earnings report date?

Fennec Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 11 days.

How were Fennec Pharmaceuticals’s earnings last quarter?

Fennec Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported €0.045 earnings per share for the quarter, beating the consensus estimate of €0.018 by €0.027.

Is Fennec Pharmaceuticals overvalued?

According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Fennec Pharmaceuticals pay dividends?

Fennec Pharmaceuticals does not currently pay dividends.

What is Fennec Pharmaceuticals’s EPS estimate?

Fennec Pharmaceuticals’s EPS estimate is 0.08.

How many shares outstanding does Fennec Pharmaceuticals have?

Fennec Pharmaceuticals has 35,067,158 shares outstanding.

What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?

Fennec Pharmaceuticals reported an EPS of €0.045 in its last earnings report, beating expectations of €0.018. Following the earnings report the stock price went up 16.578%.

Which hedge fund is a major shareholder of Fennec Pharmaceuticals?

Currently, no hedge funds are holding shares in DE:RV41

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Fennec Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-11.71%

Trailing 12-Months

Asset Growth

68.81%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals (RV41) Earnings & Revenues

Historic Earnings Reports

RV41 Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong commercial and clinical momentum: double-digit and sequential revenue growth (+78% YoY in Q2), return to positive adjusted EBITDA, record operational metrics in July, expanded commercial reach and multiple ISTs with notable forthcoming data (SIOP oral presentation). These positives are tempered by higher SG&A and marketing-driven OpEx, short-term cash timing volatility, reliance on a concentrated set of tumor types for the majority of sales, and the need for additional clinical data to drive guideline upgrades and label expansion. Management is bullish on continued growth but remains conservative on formal revenue guidance until further traction and data maturity are achieved.View all DE:RV41 earnings summaries

RV41 Stock 12 Month Forecast

Average Price Target

€15.71

▲(48.22% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","11":"€11","18":"€18","7.5":"€7.5","14.5":"€14.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17.8534128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€17.85</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.711003264,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€15.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.28273024,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.5,11,14.5,18],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,9.773339446153846,10.446678892307691,11.120018338461538,11.793357784615385,12.466697230769231,13.140036676923078,13.813376123076923,14.48671556923077,15.160055015384616,15.833394461538461,16.506733907692308,17.180073353846154,{"y":17.8534128,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,9.608538712615385,10.117077425230768,10.625616137846153,11.134154850461538,11.642693563076923,12.151232275692308,12.659770988307692,13.168309700923077,13.676848413538462,14.185387126153845,14.69392583876923,15.202464551384615,{"y":15.711003264,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.1,9.498671556923076,9.897343113846153,10.29601467076923,10.694686227692307,11.093357784615383,11.492029341538462,11.890700898461539,12.289372455384616,12.688044012307692,13.086715569230769,13.485387126153846,13.884058683076923,{"y":14.28273024,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.95,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.75,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.2,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.3,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >